Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (279)	3/18/1999 2:37:00 PM
From: JOEBT1	Read Replies (2) \| Respond to of 3158

Peter--You seem to bemoan the ineptness of large Pharma in acquiring biotech companies. In fact, of course, they have been very efficient in the acquistion of technology of small biotechs. They form a partnership with milestone payments contingent on success and " acquire" the technology they think most promising. Thus they avoid the negative bottomline burden associated with acquiring the company and get rights to the most promising technologies at "least cost". The companies most ripe for acquistion are those that are profitable or close to it--and! they have the rights to their technologies and have not farmed them to a host of partners. Agouron is a good example of an acquistion candidate--MLNM is probably not a good candidate. Glia may be attractive but they are diminishing their value with a second pipeline which will suck up profits.

To: Biomaven who wrote (279)	3/18/1999 10:12:00 PM
From: LLCF	Respond to of 3158

<AMGN, BGEN, CHIR among the biotechs, and Abbott, Bayer, DD and Schering among the pharmas, have all taken out hunting permits. Maybe I need to announce that the biotech hunting season is open? > In my experience a German fellow wouldn't be jibber jabbering like his American counterpart unless he meant to take action now... it just wouldn't make sense! It would be like.... er... ELMER FUDD! Silly! DAK

To: Biomaven who wrote (279)	3/23/1999 5:18:00 PM
From: RCMac	Read Replies (1) \| Respond to of 3158

It sounds like MEDI has also taken out a hunting permit (although it's a little unclear whether MEDI wants to munch or just to collaborate]: "MedImmune's stock is so valuable the company is on a shopping expedition, seeking deals with less-fortunate biotech firms to help them develop new drugs in exchange for a share of future profits. MedImmune also is putting finishing touches on a large factory in Frederick and testing a whole string of potentially valuable products." Article in Monday's Washington Post "MedImmune Fights Off a Virus" washingtonpost.com